| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:2832.)
© 2004 American Heart Association, Inc.
Original Contributions |
From the Departments of Medicine and Therapeutics (S.G., K.S.W.) and the Department of the Diagnostic Radiology & Organ Imaging (W.W.M.L.), the Chinese University of Hong Kong, Shatin, Hong Kong SAR; the Department of Neurology (S.G.), Peking Union Medical College Hospital, CAMS, PUMC, Beijing, China; the Department of Neurology (T.H., D.W.D., E.B.R.), University of Munster, Germany; the Service de Neurologie (D.W.D.), Centre Hospitalier de Luxembourg, Luxembourg.
Correspondence to Dr Ka Sing Wong, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR. E-mail ks-wong{at}cuhk.edu.hk
| Abstract |
|---|
|
|
|---|
Methods We prospectively monitored 114 consecutive acute ischemic stroke patients with middle cerebral artery (MCA) stenosis for MES. The signals on digital audio tape were analyzed by an independent observer who was blinded to all other data. All patients were followed-up for the occurrence of recurrent stroke or transient ischemic attack (TIA) in the indexed MCA territory.
Results MES was detected in 25 (22%) patients. The mean number of MES was 18 (range, 1 to 102). MES were more common in patients with severe stenosis (10/21, 48%) than in those with mildmoderate stenosis (4/26, 15%) (Pearson
2 P=0.02). During follow-up for a mean of 13.6 months (range, 1 to 32), 12 (12%) patients had further ischemic events (10 strokes and 2 TIAs) in the affected MCA region during follow-up. Among these, 7 (58%) had recurred within 1 month (1 recurred within 1 week, the other 6 patients had recurrences in week 3 or 4 after discharge), 3 within 6 months, 1 within 6 to 12 months, and the remaining 1 recurred after 1 year. The presence of MES was the only predictor of a further ischemic stroke/TIA by Cox regression (adjusted odds ratio, 8.45; 95% CI, 1.69 to 42.22; P=0.01) even after controlling for age, sex, diabetes, hypertension, previous stroke, smoking, and acute treatment.
Conclusions In acute stroke patients with MCA stenosis, MES predicts further cerebral ischemia. This procedure should be considered as part of routine investigation and might identify a group of patients who are most likely to benefit from antithrombotic treatment.
Key Words: arterial occlusive disease cerebral ischemia embolism microembolic signals outcome stroke transcranial Doppler
| Introduction |
|---|
|
|
|---|
With the development of transcranial Doppler ultrasound, it is possible to detect an embolus passing through the insonated artery.59 It has been suggested that they represent thrombi and platelet fibrin aggregates.6,7 Microembolic signals (MES) are found more frequently in symptomatic than in asymptomatic patients with internal carotid artery stenosis.1014 Moreover, the clinical significance of embolic signals has also been reported to be an independent predictor of future stroke.1518 A few studies have reported the presence of MES in acute stroke patients with MCA stenosis,19,20 but not in those with chronic MCA stenosis.21 However, no prospective study of the clinical significance of MES in patients with MCA stenosis has been performed. The aim of this study is to determine the frequency of embolic signals and their clinical significance in patients with MCA stenosis.
| Materials and Methods |
|---|
|
|
|---|
1000 acute stroke admissions during the study period, 114 consecutive acute stroke patients with MCA stenosis diagnosed by transcranial Doppler, who were admitted to the Prince of Wales hospital in Hong Kong, were enrolled in this study. All patients were Chinese. In our institution,
30% of stroke patients did not have an adequate temporal acoustic window for MES monitoring. Eighty-five of the 114 patients had clinical features compatible with a stroke in the stenotic MCA territory. The other 29 patients had experienced clinical symptoms on posterior circulation or on the same side as the stenotic MCA. A computed tomography scan of the head was performed to rule out intracranial hemorrhage in all patients. Presence of a poor temporal acoustic window, patient in an agitated or confused state, or presence of other potential sources of embolism, such as severe (>50%) carotid stenosis (by continuous wave ultrasound and carotid duplex) or atrial fibrillation were the exclusion criteria. Because the patients had to be examined in the ultrasound laboratory, those who were comatose, unable to comply physically with the examination, required constant bedside monitoring, or were moribund were excluded from the study.
Clinical assessments included relevant medical history, medications administered during hospitalization, and neurological examinations, which were performed by a neurologist. The definitions of the vascular risk factors adopted for this study were as follows: hypertension was diagnosed in patients who had
2 readings of systolic blood pressure
160 mm Hg or diastolic pressure
90 mm Hg documented before the onset of stroke, or a clinical history of hypertension with the use of antihypertensive medication at any time before or at the time of stroke. Diabetes was diagnosed in patients who had a history of diabetes documented by a physician, or were taking insulin or an oral hypoglycemic agent, or had a fasting blood glucose level
140 mg/dL on at least 2 occasions. For smoking status, patients were classified as having never smoked or smoked (including current smokers and ex-smokers).
The severity of neurological impairments of the index stroke was measured using the National Institutes of Health Stroke Scale (NIHSS).22,23 According to previous studies,24,25 the present study grouped the NIHSS scores as: 0 to 1 (mild stroke), 2 to 8 (moderate stroke), and
9 (severe stroke), which were entered in later analysis as a categorical variable. All patients were treated with antiplatelet therapy on discharge from hospital.
All patients were followed-up regularly for further stroke/transient ischemic attack (TIA) in the relevant MCA stenosis territory. We interviewed the patients and/or their care takrs, as well as examined the medical notes of their outpatients and inpatients record. Posterior circulation symptoms or symptoms that occurred outside this MCA territory were not recognized as further strokes. Follow-up was continued until further stroke or death. Recurrent stroke was diagnosed if the event result in a neurological deficit that was clearly different from that of the index stroke or the event involved a different anatomic site from that of the index stroke. Case ascertainments were performed without knowledge of the results of MES monitoring.
Diagnosis of MCA Stenosis
For both intracranial and extracranial arteries, including the bilateral internal carotid artery, external carotid artery, common carotid artery, and subclavian arteries, bilateral MCA, anterior cerebral artery, posterior cerebral artery, and siphon internal carotid arteries were assessed by a conventional method using the TC 2020 (Nicolet). Bilateral MCAs were insonated through the temporal window for every patient. Insonation depth was started from 56 mm, and then tracked as shallow as possible (usually
40 mm) in 4-mm decrement steps and recorded at each depth. The insonation depth was set at 56 mm again, and then increased progressively to proximal depth, usually
66 mm. The TCD spectrum was recorded in each 4-mm decrement. At each depth, the probe position was adjusted until the highest Doppler frequency was obtained. Maximum systolic flow velocity was recorded.
The TCD criteria for diagnosis of MCA stenosis were systolic flow velocity >140 cm/s, with side-to-side difference and disturbed flow (turbulence). The severity of MCA stenosis in TCD was graded as 140 to 180 cm/s and >180 cm/s as previously validated.26 The severity of MCA stenosis on MRA was classified as mildmoderate stenosis (30% to 75%) or severe stenosis (>75%) according to the lumen reduction and amount of signal loss.
Microembolic Signal Detection
MES detection was performed immediately after conventional TCD examination with a TC 2020 machine (Nicolet-EME). Within 3 days after the onset of symptoms, MES monitoring was performed for all patients. Depths in the stenotic or distal segment of the affected MCA were insonated trough the temporal window for 30 minutes. A 2-MHz bi-gate transducer was fixed to the head with the Marc 500 TCD probe fixation head frame (Spencer Technologies). The upstream depth of insonation was targeted at the stenotic segment and the downstream depth was targeted 8 to 10 mm distally. A small sample volume 6 mm in length and a low gain were used. A detection threshold of
5 dB was used.27 The machine used a 128-point FFT analysis and used a graded color scale to display the intensity of the received Doppler signal. FFT time frame overlap was 61% to 71%. In addition, data were continuously recorded onto a 4-channel digital audio tape recorder (TA-88; TEAC Corporation) with normal speed. The recorded data were then analyzed by an experienced observer, who was blinded to the clinical and laboratory data. The number of MES during the 30-minute recording was noted. The following definitions for emboli signals were used: typical visible and audible (click, chirp, whistle) short-duration, high-intensity signal within the Doppler flow spectrum with its occurrence at random in the cardiac cycle, and an intensity increase of
5 dB above the background signal.5
Statistical Analysis
All data were entered into SPSS version 9.0 for Windows for analysis. The statistical significance was considered at 0.05 and was 2-sided.
Flow velocity difference between MES-positive patients and MES-negative patients was assessed with 1-way ANOVA. The severity of stroke on admission or the course of stroke during hospitalization between MES-positive patients and MES-negative patients was assessed by the Pearson
2 test.
The relationship between MES and recurrent stroke-affected MCA territory was determined from the KaplanMeier method. The censored data were nonischemic stroke and death. Cox regression was used to assessing the other risk factors.
| Results |
|---|
|
|
|---|
There was no significant association between the presence of MES and age, sex, diabetes and hypertension, smoking, or previous stroke (P=0.44, 0.59, 0.64, 0.44, 0.88, and 0.05 respectively). The association between therapeutic agent given after admission and the presence of MES was not assessed because treatment and MES monitoring were usually begun on the same day. The median NIHSS on admission was 3 (range, 0 to 18). The median NIHSS on admission was 3 in MES-positive patients and 3 in MES-negative patients. Twenty-five percent of patients had mild stroke, 55% had moderate stroke, and 17% had severe stroke. Among 47 patients who underwent magnetic resonance angiography examination, MES were more common in patients with severe stenosis (10/21, 48%) than in those with mildmoderate stenosis (4/26, 15%) (Pearson
2, P=0.016; Table 1).
|
Correlation Between the Presence of MES and Further Ischemic Stroke/TIA
Mean±SD time of follow-up was 13.6 months (range, 1 to 32 months). Twelve (12.2%) patients had further ischemic events (10 strokes and 2 TIAs) in the affected MCA region during follow-up (Table 2). Among these, 7 (58%) had recurred within 1 month (1 recurred within 1 week, the other 6 patients recurred in week 3 or 4 after discharge), 3 within 6 months, 1 within 6 to 12 months, and the remaining 1 recurred after 1 year. Six of these 12 patients (50%) were MES-positive. Nine patients died during follow-up. The causes of death were cerebral hemorrhage on the contralateral side (2 patients), nonvascular disease (eg, cancer or pneumonia in 4 patients), or unknown causes (3 patients). By KaplanMeier nonparametric survival analysis, a significant association was found between MES and further incidences of stroke (log rank, 5.96; P=0.01; Figure)
|
|
The presence of MES was predictive of a further ischemic event (unadjusted odds ratio, 3.94; 95% CI, 1.18 to 13.7; P=0.03). After controlling for age, sex, diabetes, hypertension, smoking, degree of stenosis, previous stroke, and therapeutic agents (anticoagulant or aspirin), the adjusted odds ratio became 8.45 (95% CI, 1.69 to 42.22; P=0.01) (Table 3).
|
| Discussion |
|---|
|
|
|---|
Predictive Value of MES for Future Stroke
Previous studies had shown that the presence of MES was predictive of increased risk of future cerebral ischemia in patients with symptomatic or asymptomatic internal carotid artery stenosis, carotid endarterectomy, and patients with stroke or TIA of presumed arterial origin.1518,31,32 Retrospective data reported by Babikian et al showed that further cerebral or retinal ischemic events occurred in the territory of MES-positive arteries than in the territory of MES-negative arteries.17 Molley et al demonstrated that asymptomatic embolization in patients with carotid artery stenosis correlates with known markers of increased stroke risk and is an independent predictor of future stroke risk in patients with both symptomatic and asymptomatic carotid stenosis.16 The results of our prospective follow-up study provide the first data to our knowledge that the presence of MES independently predicted future risk of cerebral ischemia in patients with MCA stenosis. These results suggest that stable atherosclerotic MCA stenoses (those without MES) remain silent, whereas unstable MCA stenoses (those with MES) cause further cerebral ischemia. Increased flow velocity, decreased residual lumen, and increased systemic risk factors associated with increased blood thrombogenicity or a systemic hypercoagulable state will increase the risk of thrombosis and subsequent embolization. A retrospective study reported a favorable risk/benefit ratio for warfarin compared with aspirin for the prevention of major vascular events with symptomatic intracranial large-artery stenosis.33
In summary, this study confirmed the clinical significance of MES in the acute stage and predicted further cerebral ischemia. Our data support further studies to explore the potential of MES detection as a means to monitor the effect of antithrombotic treatments in stroke patients.
| Acknowledgments |
|---|
Received January 9, 2003; revision received June 3, 2004; accepted August 3, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Poppert, S. Sadikovic, K. Sander, O. Wolf, and D. Sander Embolic Signals in Unselected Stroke Patients: Prevalence and Diagnostic Benefit Stroke, August 1, 2006; 37(8): 2039 - 2043. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |